X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IMVT-1402 is designed to be a potentially best-in-class neonatal anti-FcRn antibody, which is being evaluated for the treatment of IgG-mediated autoimmune diseases.
Lead Product(s): IMVT-1402
Therapeutic Area: Immunology Product Name: IMVT-1402
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
The net proceeds will fund the acceleration of IMVT-1402 development. IMVT-1402 is designed to be a potentially best-in-class anti-FcRn antibody for the treatment of IgG-mediated autoimmune diseases.
Lead Product(s): IMVT-1402
Therapeutic Area: Immunology Product Name: IMVT-1402
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: $492.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 02, 2023
Details:
The net proceeds will fund the acceleration of IMVT-1402 development. IMVT-1402 is designed to be a potentially best-in-class anti-FcRn antibody for the treatment of IgG-mediated autoimmune diseases.
Lead Product(s): IMVT-1402
Therapeutic Area: Immunology Product Name: IMVT-1402
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: $450.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 27, 2023
Details:
The net proceeds will fund the acceleration of IMVT-1402 development. IMVT-1402 is designed to be a potentially best-in-class anti-FcRn antibody for the treatment of IgG-mediated autoimmune diseases.
Lead Product(s): IMVT-1402
Therapeutic Area: Immunology Product Name: IMVT-1402
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leerink Partners
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 26, 2023
Details:
IMVT-1402 is designed to be a potentially best-in-class anti-FcRn antibody for the treatment of IgG-mediated autoimmune diseases. In the initial results of a Phase 1 clinical trial in healthy volunteers, IMVT-1402 demonstrated favorable pharmacodynamic and safety data.
Lead Product(s): IMVT-1402
Therapeutic Area: Immunology Product Name: IMVT-1402
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
The company intends to use the net proceeds from this offering, together with its existing cash, to accelerate the development of IMVT-1402 (batoclimab), including the funding of a proposed pivotal trial.
Lead Product(s): Batoclimab
Therapeutic Area: Immunology Product Name: IMVT-1401
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: SVB Securities
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 04, 2022
Details:
As with batoclimab, (IMVT-1402), potentially best-in-class IgG reduction formulated for same simple subcutaneous route of administration delivered in matter of seconds. IMVT1402 has been observed to have minimal or no impact on levels of albumin and LDL in animal studies.
Lead Product(s): Batoclimab
Therapeutic Area: Immunology Product Name: IMVT-1402
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
The Company’s investigational compound, HBM9161 (batoclimab), is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn)in Chronic Inflammatory Demyelinating Polyneuropathy and Graves’ Disease.
Lead Product(s): Batoclimab
Therapeutic Area: Neurology Product Name: HBM9161
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
The trial will include an induction (primary efficacy) period during which Immunovant plans to study doses of 680mg and 340mg of batoclimab delivered weekly by subcutaneous injection.
Lead Product(s): Batoclimab
Therapeutic Area: Immunology Product Name: HBM9161
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2021
Details:
Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. Proceeds will fund continued development of IMVT-1401 in multiple indications.
Lead Product(s): IMVT-1401
Therapeutic Area: Immunology Product Name: RVT-1401
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Roivant Sciences
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 02, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
